Actively Recruiting
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Led by University of Leicester · Updated on 2026-04-30
60
Participants Needed
1
Research Sites
590 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs. The condition often requires multiple admissions to hospital and is associated with a marked loss of lifespan. Despite being so common, very little is known about why people develop HFpEF and there are hardly any known treatments. Type 2 diabetes (T2D) is a major risk factor for HFpEF, and people with both HFpEF and diabetes are at a heightened risk of hospitalisation and premature death. It is unclear why the combination of diabetes and HFpEF is particularly harmful. This may be related to the hearts of people with type 2 diabetes being unable to take up the mineral calcium properly, as well as due to their hearts being less energy efficient. Both of these are vital to heart muscle pumping and filling, but until recently it has not been possible to assess these in humans. New advances in heart MRI scans, with dedicated scanner techniques and dyes (manganese contrast), now allow extremely detailed pictures of heart structure, function, calcium uptake and energy efficiency, all during the same scan. The investigators will enlist 40 volunteers with HFpEF (20 with T2D and 20 without T2D), and up to 20 healthy volunteers, to undergo a heart MRI scan with manganese contrast to assess calcium uptake and energy efficiency. This will allow the comparison of people with HFpEF with and without T2D, to see how their hearts are different to healthy volunteers.
CONDITIONS
Official Title
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capacity to provide informed consent
- Symptoms such as breathlessness, orthopnoea, ankle swelling, or fatigue, or signs such as elevated jugular venous pressure, peripheral oedema, or third heart sound, or an established diagnosis of heart failure with left ventricular ejection fraction 50% or higher
- Meets heart failure with preserved ejection fraction diagnostic criteria according to the HFA-PEFF diagnostic algorithm with a score of 5 or more points
You will not qualify if you...
- Known diagnosis of type 1 diabetes
- Pregnancy, breastfeeding, or females of childbearing age without a negative pregnancy test
- Receiving an investigational drug or device within 30 days prior to study participation
- Decompensated heart failure or pulmonary oedema
- History of prolonged corrected QT interval or torsades de pointes
- Second- or third-degree atrioventricular block
- Abnormal liver function tests greater than three times the upper limit of normal or history of liver disease
- Baseline estimated glomerular filtration rate less than 30 mL/min/1.73 m2
- Any contraindications to MRI including implanted devices or pacemakers
- Severe native valve disease, restrictive cardiomyopathy, constrictive pericarditis, hypertrophic cardiomyopathy, myocarditis, or takotsubo cardiomyopathy
- Recent myocardial infarction within the previous 3 months
- Known diagnosis of pheochromocytoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Leicester
Leicester, United Kingdom
Actively Recruiting
Research Team
G
Gerry P McCann, MD
CONTACT
A
Abhishek Dattani, MBBS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here